Worth reading
63In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
1
caseWording
Definitive
How definitive the wording is.Announced details
Regenerative medicine product “ReHeart®”
Applicable field (uses covered by this announcement)
Transplantation of regenerative medicine products under covered medical care
Launch date29 September 2026 (completed; first transplant since listing for insurance coverage)
What the company reported numerically
Usage history
First transplant performed since listing for insurance coverage
Relationship between the counterparty and the company
Cuorips Inc.4894
Relationship with the Company
Medical institution where the regenerative medicine product developed by the Company was transplanted
CounterpartyOsaka Keisatsu Hospital
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative medicine product “ReHeart®” |
| Counterparty | Osaka Keisatsu Hospital |
| Relationship with the Company | Medical institution where the regenerative medicine product developed by the Company was transplanted |
| Launch date | 29 September 2026 (completed; first transplant since listing for insurance coverage) |
| Applicable area | Transplantation of regenerative medicine products under covered medical care |
| Usage history | First transplant performed since listing for insurance coverage |
Items this document does not state (12)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The product became available for use under covered medical care after being listed for insurance coverage. Going forward, the Company will strengthen collaboration with medical institutions and work to ensure safety and promote adoption.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.